Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAPTIVATE demonstrates encouraging results in CLL

Wierda WG et al. ASCO 2018, Abstract 7502.

Publish date:: June 27, 2018

Key clinical point: Ibrutinib plus venetoclax produced a high rate of undetectable minimal residual disease.

Major finding: Of 14 patients, 12 (86%) who completed 12 cycles of treatment had undetectable bone marrow MRD.

Study details: Early results of the phase 2 CAPTIVATE trial including 164 patients younger than 70 years of age with previously untreated CLL.

Disclosures: The study was sponsored by Pharmacyclics, an Abbvie company. Dr. Wierda reported consulting and research funding from Pharmacyclics, AbbVie, and several other companies.

Read the article.

Citation:

Wierda WG et al. ASCO 2018, Abstract 7502.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,